Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.64 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363690 | 0.88 | ALDH1A1 (0.63) | SIRT2SIRT1HTTMEN1KMT2A | |
| SCHEMBL28670399 | 0.87 | SIRT1 (0.63) | SIRT2SIRT1TRPV1 | |
| SCHEMBL4362115 | 0.87 | SIRT2 (0.60) | SIRT2SIRT1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16229451 | 0.86 | SIRT1 (0.64) | SIRT2SIRT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4368732 | 0.85 | SIRT1 (0.56) | SIRT2SIRT1HTTMEN1KMT2A | |
| SCHEMBL4360377 | 0.85 | SIRT2 (0.56) | SIRT2SIRT1HTTSMN1; SMN2MEN1 | |
| SCHEMBL16229389 | 0.85 | SIRT2 (0.86) | SIRT2SIRT1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3718452 | 0.85 | SIRT2 (0.67) | SIRT2SIRT1MEN1KMT2APLK1 | |
| Hydrochloric Acid SCHEMBL3718449 | 0.85 | SIRT2 (0.67) | SIRT2SIRT1MEN1KMT2APLK1 | |
| SCHEMBL4371803 | 0.84 | ALDH1A1 (0.64) | HTTSMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | claimed |
| EP-1562895-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004046095-A1 | SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-7094807-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, TPMT | SIRT2 774/4885SIRT1 767/4885HTT 927/4885 |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | SIRT2 4612/4885SIRT1 4376/4885HTT 3396/4885 |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, SLC10A1 | SIRT2 1118/4885SIRT1 1017/4885HTT 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.